Literature DB >> 9175826

Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient.

S Alain1, P Honderlick, D Grenet, M Stern, C Vadam, M J Sanson-Le Pors, M C Mazeron.   

Abstract

We report the case of a lung transplant recipient with progressive cytomegalovirus (CMV) disease due to a resistant CMV strain emerging under ganciclovir (GCV) therapy. A discriminative polymerase chain reaction (PCR) assay, designed to detect the resistance-related V460 mutation within the viral enzyme UL97, revealed the presence of a mutated strain in a heterogeneous isolate 51 days after transplantation. The conventional antiviral susceptibility assay had failed to demonstrate resistance to GCV. Under prolonged GCV therapy, the mutated strain dominated the wild-type strain, as shown by the PCR assay. This domination led to laboratory resistance, associated with recurrent fever and progressively severe retinitis. As this discriminative PCR assay was shown to be effective in detecting mutated strains that constitute a minority in the virus load, it should allow better management of patients with CMV disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175826     DOI: 10.1097/00007890-199705270-00031

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

1.  Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I.

Authors:  Anne-Marie Fillet; Laetitia Auray; Sophie Alain; Karine Gourlain; Berthe Marie Imbert; Fatiha Najioullah; Gael Champier; Stéphanie Gouarin; Jocelyne Carquin; Nadhira Houhou; Isabelle Garrigue; Alexandra Ducancelle; Danielle Thouvenot; Marie-Christine Mazeron
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir.

Authors:  Gyu-Cheol Lee; Dong-Gun Lee; Su-Mi Choi; Jin-Hong Yoo; Sun-Hee Park; Jung-Hyun Choi; Woo-Sung Min; Ok-Hee Cho; Chan-Hee Lee; Wan-Shik Shin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Oral ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients: is emergence of resistance imminent?

Authors:  N Singh; V L Yu
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

Review 4.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

5.  Diagnostic implications of human cytomegalovirus immediate early-1 and pp67 mRNA detection in whole-blood samples from liver transplant patients using nucleic acid sequence-based amplification.

Authors:  M J Blok; I Lautenschlager; V J Goossens; J M Middeldorp; C Vink; K Höckerstedt; C A Bruggeman
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient.

Authors:  Fengshi Chen; Toru Bando; Nobuharu Hanaoka; Tatsuo Fukuse; Seiki Hasegawa; Hiromi Wada
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-10

7.  Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.

Authors:  N S Lurain; A Weinberg; C S Crumpacker; S Chou
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 8.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 9.  Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.

Authors:  Javier Bueno; Carmen Ramil; Michael Green
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.

Authors:  C Gilbert; J Roy; R Belanger; R Delage; C Beliveau; C Demers; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.